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Introduction
In Europe and in North America, portal hypertension
accompanies cirrhosis of the liver in over 90 % of the
cases. Cirrhosis of the liver is caused by alcohol abuse in
about half of the cases; a third is due to chronic viral
hepatitis B and C; and the remainder is the result of various
metabolic or idiopathic disorders of the liver.
Transjugular intrahepatic portosystemic shunting, as a
percutaneous alternative to surgical portosystemic shunts
for decompression of symptomatic portal hypertension,
was conceived and its technique developed in animal
experiments in the late 1960s by Ro¨sch et al. [1].
Definitions
Portal hypertension is a syndrome caused by increased
resistance in the portohepatic circulation and an increase in
the splanchnic vein blood supply. In the normal liver, the
difference between pressures in the portal vein and the free
hepatic veins or right atrium usually does not exceed 5 mm
Hg. Portal hypertension is defined as a gradient larger than
6 mm Hg, but clinical complications seem to occur only
when the pressure gradient exceeds 10–12 mm Hg.
Wedged hepatic pressure measurement has two com-
ponents. The portal component is the pressure transmitted
from the hepatic sinusoids, and the systemic component is
the blood pressure transmitted from the central veins. It is
the portal component that causes the development of portal
systemic collaterals. The term corrected sinusoidal pres-
sure includes only the portal component and is calculated
by subtracting the mean right atrial or inferior vena cava
pressure from the wedged hepatic venous pressure.
Wedged hepatic pressure is obtained through an end-hole
catheter that is advanced into a hepatic vein until it can go
no further. Alternatively, pressure can be measured through
the wire channel of a double lumen balloon catheter
inflated in a more central vein.
Transjugular intrahepatic portosystemic shunt (TIPS) is
the percutaneous method of creating a portosystemic shunt
to decrease or treat portal hypertension. TIPS is a side-to-
side shunt of a determined diameter designed to function as
a partial shunt that preserves a portion of portal flow to the
liver [2]. Flow through the completed shunt is assessed by
comparing the degree of preferential filling of the shunt to
the that of the portal vein branches and portosystemic
collaterals (mainly in the gastric veins). The identification
of hepatofugal (reversed) blood flow in portal vein bran-
ches (total shunting) is a sign of good flow through the
shunt.
Technical success is defined as a decrease of the por-
tosystemic pressure gradient to 12 mm Hg or less, or a
reduction of at least 20 %.
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Clinical success is defined as cessation of variceal
bleeding, decrease of ascites, and conversion into diuretic-
sensitive ascites, as well as improvement of liver function in
patients referred for massive thrombosis of hepatic veins.
Hepatic encephalopathy is defined as the complex of all
cerebral dysfunctions that can occur during the course of seri-
ous liver disease. Clinical symptomatology, which as a rule is
potentially reversible, ranges from disorientation, somnolence,
and lethargy to sopor and coma. Hepatic encephalopathy has
three forms: type A, associated with acute liver failure; type B,
associated with portosystemic bypass without liver disease; and
type C, or chronic, associated with liver cirrhosis.
Pretreatment Imaging
Ultrasonography should verify portal and hepatic vein
patency; exclude intrahepatic tumor or cyst; determine
maximum blood flow velocities in the portal vein; measure
diameters and the congestion index of the main portal,
superior mesenteric, and splenic veins; evaluate splenic
size; and document the presence and extent of portosys-
temic collaterals and ascites. This evaluation is the baseline
for comparisons to be made during follow-up.
Computed tomography (CT) should identify distortion
of liver anatomy including lobar atrophy and size of the
liver, and evaluate the spatial relationships of the liver and
the right kidney, hepatic veins, and portal vein branches.
Patency of the portal vein and its tributaries, focal liver
lesions, and amount of ascites are also identified by CT.
Magnetic resonance imaging measures hepatic flows
using a phase contrast technique and provides the most
specific imaging diagnosis of the hepatocellular carcinoma
using liver cell-specific contrast agent [3].
Indications for Treatment and Contraindications
TIPS Indications
Generally, patients with a Child-Pugh score of [12 are in
high risk of postprocedural death. A thorough selection of
patients is the key to successful treatment with TIPS.
Scoring of patients by the model of end-stage liver disease
(MELD) has been validated to predict early mortality after
TIPS. Patients with MELD scores of[15–18 or a bilirubin
level of [60 lmol/L (3.5 mg/dl) should be informed of
their poor prognosis, and TIPS should only be performed in
the absence of any other treatment possibilities.
Refractory Ascites
Refractory ascites is the most frequent indication for TIPS.
Refractory ascites is defined as an abdominal fluid collection
that cannot be mobilized or the early recurrence of abdominal
fluid that cannot adequately be prevented by medical therapy
[2]. The term refractory ascites has two different meanings:
diuretic-resistant ascites and diuretic-intractable ascites.
Diuretic-resistant ascites does not respond to an intensified
diuretic treatment of up to 400 mg/day spironolactone, up to
160 mg/day of furosemide, and sodium restriction to a max-
imum intake of 5.2 g of salt/day. Diuretic-intractable ascites
cannot be mobilized or their early recurrence cannot be pre-
vented because of the development of diuretic-induced com-
plications that preclude the use of an effective diuretic dosage.
Two important complications occur in patients with
cirrhotic ascites: spontaneous bacterial peritonitis and
hepatorenal syndrome [4, 5].
Hepatic hydrothorax occurs in patients with ascites
when there is direct communication between the peritoneal
and pleural cavities. In most patients, the defect is in the
diaphragm that overlies the dome of the liver. Hepatic
hydrothorax is due to an accumulation of ascitic fluid
migrating through the diaphragmatic defect [6].
Variceal Bleeding
The causes of gastrointestinal hemorrhage in a patient with
portal hypertension may be variceal rupture, portal hyper-
tension gastropathy, postsclerotherapy ulcers, peptic ulcer
disease, hemorrhagic gastritis, and Mallory-Weiss tear.
TIPS is generally accepted as a second-line therapy after
failure of endoscopic and medical therapy of bleeding from
gastroesophageal varices.
Massive Thrombosis of the Hepatic Veins
TIPS is indicated when medical therapy fails. TIPS is tech-
nically feasible in most patients with thrombosis of the
hepatic veins. A direct puncture from the intrahepatic inferior
vena cava into the liver parenchyma is possible in patients
without a remaining hepatic vein stump. The rationale of the
use of TIPS is to decompress the liver from venous congestion
using the portal vein and TIPS as an outflow tract.
Portal Vein Thrombosis
TIPS should be considered in patients with portal vein
thrombosis with or without cavernomatous transformation.
TIPS can be technically feasible when intrahepatic portal
branches are patent. The procedure should be referred to
centers with extensive experience [7].
Portosystemic Collaterals Embolization
There are three main indications for occluding large por-
tosystemic collaterals. The most frequent is embolization
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of the left and short gastric veins in a patient with a recent
history of acute variceal bleeding, especially if the bleeding
source was gastric varices. Another indication is closure of
large collaterals with continuing competitive flow after
TIPS. In addition, patients with a history of portosystemic
encephalopathy or patients at high risk for that condition
may benefit from embolization of large portosystemic
collaterals performed during calibrated TIPS.
TIPS Contraindications
TIPS is absolutely contraindicated in cases of unproved
portal hypertension (either clinically or anatomically).
TIPS should be carefully considered in the following
circumstances: APACHE II score[20, especially in Child
C patients, and irreversible phase of hemorrhagic shock;
Child-Pugh score [12 and MELD score [18; right-sided
heart failure with elevation of the central venous pressure
(mean right atrium pressure [15 mm Hg); hepatic
encephalopathy poorly controlled by lactulose, especially
in patients older than 60, patients with diabetes, and
patients receiving hemodialysis; chronic occlusion of the
portal vein with periportal collaterals, hypervascular
hepatic tumors, polycystic liver disease; and active infec-
tion, either intrahepatic or systemic.
To provide TIPS for variceal bleeding, the following
laboratory values are required: total bilirubin \60 lmol/L
(3.5 mg/dl), especially in Child C patients; and corrected
international normalized ratio (INR) of \1.8. To provide
TIPS for refractory ascites, the following laboratory values
are required: total bilirubin \50 lmol/L (3 mg/dl); and
serum creatinine of \180 lmol/L (2.1 mg/dl), except in
cases of hepatorenal syndrome. Elevated total serum bili-
rubin level can also be due to biliary obstruction, hemo-
bilia, hemolysis, or primary biliary cirrhosis. In such cases,
values of [60 lmol (3.5 mg/dl) are not a contraindication
for TIPS.
The encephalopathy test and the anatomic ultrasound
and CT studies can be excluded when a patient is acutely
bleeding and cannot undergo endoscopic therapy.
Patient Preparation
Laboratory tests are performed to reveal coagulopathy,
liver and renal failure, and systemic infection, as well as to
establish Child-Pugh classification (i.e., prothrombin time/
INR, partial thromboplastin time, creatinine, urea, elec-
trolytes, bilirubin, total protein, complete blood count,
transaminases). The operator should know at least these
values to assess and minimize potential risks arising from
iodinated agent administration, structural liver injuries, and
overshunting of the portosystemic blood flow [8].
Subclinical hepatic encephalopathy is revealed using a
number connecting test. The patient’s signature should be
documented in the chart every day.
To improve the patient’s clinical state, hematocrit,
protein, coagulation deficit (fresh frozen plasma if INR is
[1.8, platelet infusion if count is \50,000 9 109/L, or
according to the center’s standards) should be corrected.
The acutely bleeding patient has to be hemodynamically
stabilized during the procedure.
Cardiologic evaluation should reveal preexisting cardiac
dysfunction. Silent cirrhotic cardiomyopathy may be
unmasked after TIPS insertion [9].
Prophylactic broad-spectrum antibiotics should be
administered. With a potentially limited effect on hepatic
metabolism, antibiotics are initiated on the day of proce-
dure and continued for at least two additional days.
(Antibiotic therapy should be included in the therapy of
variceal bleeding.)
Two cross-matched blood units should be available.
Draining of tense ascites can be performed to decrease
the angle between the hepatic veins and the inferior vena
cava and have better fluoroscopic imaging. Clinicians
should be aware of hepatorenal syndrome. Monitored
ascites drainage can improve respiratory comfort during
the procedure.
It should be determined whether patients have an allergy
to contrast media. In patients with a history of idiosyncratic
reaction to iodinated contrast media, a reaction rate of
16–44 % (i.e., 4–8 times more that of the general popula-
tion) has been reported upon reexposure. Pretreatment with
corticosteroids at least 12 h before the administration of
contrast medium is recommended to prevent adverse
reaction.
Patients should be instructed to restrict their oral intake
for at least 6–8 h before the procedure.
Placement of a reliable intravenous line should be
possible.
Informed consent—a comprehensive description and an
explanation of the reasons for this therapy, including
potential consequences—must be provided to the patient or
patient’s family. Alternative therapies should be mentioned.
Equipment Specifications
Monoplane digital subtraction angiography equipment that
is capable of performing standard projections, including
lateral view, should be available. This equipment should
provide high-quality fluoroscopy with zooming and refer-
ence imaging. The catheterization laboratory should be
equipped with ultrasonography to navigate puncture of the
jugular and portal veins. Transcatheter blood pressure
measurement should be available during the procedure.
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There are two TIPS needle-set designs. The first is a
relatively simple set, consisting of a 15- to 16-gauge,
55-cm-long, curved steel needle and teflon catheter. The
needle has a sharp, reversed bevel at its distal tip. The
puncture is made by advancing the entire device through a
liver parenchyma. Correct portal vein access is verified by
blood return upon aspiration by a 10 ml syringe filled with
contrast medium. The contrast medium is used for imme-
diate opacification of the portal vein (excluding accidental
puncture of the hepatic artery or biliary duct). Once the
portal vein branch is filled with good distal flow, a 180-cm-
long stiff guide wire is introduced through the stiff curved
cannula. A modification of this set is available that consists
of a blunt outer cannula and sharp inner mandril.
The second type of needle set consists of a 14-gauge
metal cannula covered with thin-walled teflon catheter.
Inside this long cannula is a needle covered with 5F teflon
tapered tip catheter. The cannula secures the wedged
position of the set inside the hepatic vein, and its curved tip
controls the direction of the puncture. The cannula itself
does not cross the parenchyma during each needle pass.
Instead, the puncture is made by a forceful push of the
0.038 inch needle toward the portal vein branch while the
metal cannula is held in wedged position in the hepatic
vein. When this sheathed needle is used, the diameter of the
puncture hole is approximately 1.7 mm (i.e., 5F).
Also available is a pediatric TIPS set, which includes a
0.018 inch guide wire instrumentarium.
Procedure
After entry into the internal jugular vein, a catheter is
introduced and guided through the superior vena cava, right
atrium, and inferior vena cava into a hepatic vein—usually
the right hepatic vein. Wedge hepatic pressure measure-
ment follows. The use of the proximal portion of the
hepatic vein has two purposes. The first is to utilize, for
shunt creation, the largest diameter of the hepatic vein to
potentially prevent or delay any outflow shunt stenosis. The
second is to be sure that one begins cephalad to the desired
portal vein entry site. A needle inserted through the cath-
eter is then used to puncture the liver from a central portion
of the hepatic vein and enter the main portal branch, usu-
ally the right portal vein. In the right hepatic vein, the
cannula is rotated approximately 90 anteriorly and then
advanced and maintained with continual caudal pressure
such that it is wedged against the wall of the hepatic vein.
When in the middle hepatic vein, the cannula is rotated
posteriorly in the some way. Carbon dioxide wedged
hepatic venography is used to identify the portal vein [10].
The puncture can be also navigated with ultrasonography.
Depending on the anatomy, it might by possible to use a
tract from the right hepatic vein to the left portal branch,
and vice versa. The needle tract is then dilated by a balloon
catheter, establishing a connection between the portal and
systemic circulation directly inside the liver parenchyma.
The parenchymal tract is kept open by insertion of an
expandable metallic stent. A dedicated TIPS stent graft was
designed to extend the covered portion to the orifice of the
hepatic vein at the inferior vena cava. The only noncovered
part of the stent graft, which is 2 cm long, is that part which
protrudes into the portal vein. This both anchors the device
and allows blood to flow through the interstices of the
noncovered portion to the peripheral (parenchymal) portal
vein branches.
From the early TIPS experience, the alternative to the
dedicated stent graft has been a self-expandable stent used
for bridging portal and hepatic veins in a similar way. The
bare stents are used for patients at high risk of hepatic
encephalopathy or for recanalization of the portal vein. The
shunt diameter is finalized by balloon dilatation of the
deployed stent graft or stent.
Depending on the diameter of the expandable stent or
stent graft used for TIPS creation, various amounts of
portal blood are diverted into the systemic circulation,
resulting in the decompression of portal hypertension. The
size of the balloon catheter is usually 8 mm. Depending on
the pressure gradient measured between the portal vein and
right atrium after stent or stent graft placement, the larger
angioplasty balloon catheter can be used to achieve ade-
quate stepwise decompression.
For patients who are liver transplant candidates, precise
positioning of both ends of the stent or stent graft is critical
[11].
The needle may exit the liver and lacerate the liver
capsule or enter the hepatic artery. Embolization of the
parenchymal tract is the first-line treatment to prevent
hemoperitoneum.
The TIPS tract must be intraparenchymal, or dilatation of
the extrahepatic portion of the portal vein results in fast
exsanguination. The frequency of this complication is about
1 %. Entry into the right or left portal vein branch should be
at least 1 to 2 cm from the portal vein bifurcation. The direct
injection into the dilated tract should be done as soon as
possible to reveal potential extravasation. If it is positive, the
balloon is again inflated and the stent graft placed to tam-
ponade the extrahepatic leak. According the patient’s blood
pressure, fluid volume resuscitation is immediately initiated
and the anesthesiologist is called [11].
The final step of the TIPS procedure is placement of
pigtail catheter over the portal vein guide wire for follow-
up portography and pressure measurement. The post-TIPS
blood pressure is measured within the main portal vein.
Once the value is stabilized and recorded, the tip of the
sheath or pigtail catheter is moved to the hepatic vein or the
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suprahepatic inferior vena cava, and the blood pressure is
again recorded. Thus, at the completion of the TIPS pro-
cedure, at least four pressure values will have been
obtained: those in the portal vein and hepatic vein (or
inferior vena cava) before and after shunt placement.
Monitoring Patients During TIPS
The TIPS procedure can be performed with conscious
sedation in most patients, although children, critically ill or
uncooperative patients, and those on artificial ventilation
may require general anesthesia. The routine use of general
anesthesia is preferred in some centers.
Conscious sedation requires careful patient monitoring
and the assistance of a nurse. Midazolam and fentanyl are
routinely used with the administration of supplemental
oxygen through nasal prongs or a face mask under con-
tinuous oxygen saturation monitoring with a pulse oxime-
try probe and regular blood pressure measurement. These
medications are provided in addition to local skin anes-
thesia to alleviate the considerable pain that accompanies
dilatation of the shunt tract. The intensity of pain varies
from patient to patient.
Continuous electrocardiogram monitoring is also
required, especially while maneuvering the entry guide wire
from the right atrium into the inferior vena cava during
inadvertent catheter or wire passage into the right ventricle.
The contact of catheters or wires with the inner walls of the
right atrium or ventricle can cause severe arrhythmias.
Postprocedural Follow-up
All TIPS patients are followed by serial duplex ultraso-
nography at 24 h, 1, 3, and 6 months after the TIPS
placement, then every 6 months thereafter [12, 13].
An upper endoscopy is scheduled at 6 months in
patients treated for gastrointestinal bleeding as a comple-
mentary assessment. The patients are continually followed
by a hepatologist.
Anticoagulation is not routinely recommended except in
patients treated for massive thrombosis of the hepatic veins
(Budd-Chiari syndrome). In these cases, strict anticoagu-
lation is mandatory to keep the INR above 2.
Occurrence of hepatic encephalopathy or its worsening is
revealed by direct question of the patient, or by obtaining
information by asking family members. Specific questions
are asked regarding changes in personality, working capac-
ity, sleep behaviors, and power of concentration. There are
psychometric tests for the early detection of subclinical
encephalopathy, including study of a handwriting specimen,
a number-connection test, and a line-tracing test.
When a polytetrafluoroethylene-covered stent graft is used,
hepatic encephalopathy may be frequent; unlike bare stents, its
occurrence tends to be constant during follow-up. Refractory
hepatic encephalopathy can be managed by reducing the shunt
diameter via various stenosing devices [14, 15].
Outcome
Unpredictable shunt patency remains the greatest problem
with this method. With conventional bare metal stents, the
probabilities of shunt dysfunction after the primary proce-
dure are*25 and 50 % after 6 and 12 months, respectively.
Creation of a TIPS with the use of expanded polytetrafluo-
roethylene (ePTFE)-covered stent grafts has been reported
to reduce the incidence of shunt dysfunction to 13 % at
6 months and 15–20 % at 1 year. The use of ePTFE-covered
stent grafts has dealt with the main problem of primary TIPS
dysfunction [13]. Similarly, ePTFE-covered stent grafts also
have a place in the secondary prevention of TIPS dysfunc-
tion and can improve long-term patency [15–19].
Multiple trials and meta-analyses report much better
control of refractory ascites with TIPS than with large-
volume paracenteses. TIPS may convert diuretic-resistant
ascites into diuretic-sensitive ascites. However, survival
and transplant-free survival are similar with the two tech-
niques. Encephalopathy occurs more often in patients
treated with TIPS than patients with large-volume para-
centeses [20, 21]. TIPS results in improvement of renal
function, as indicated by a decrease in serum creatinine and
blood urea nitrogen levels [22].
TIPS is effective in controlling acute bleeding from
varices refractory to medicamentous therapy, and TIPS
should be used in preference to surgery. TIPS should be
performed only if pharmacologic and endoscopic therapy
have failed in the prevention of variceal rebleeding or when
rebleeding occurs after sclerotherapy, and in high-risk
patients after the first bleeding attack (hepatic venous
pressure gradient [20 mm Hg, or Child-Pugh class B and
C with active bleeding during endoscopy) [23].
TIPS should be used in the management of patients with
massive thrombosis of hepatic veins whose condition fails
to improve with anticoagulation. A large retrospective
study revealed 1 and 10 year transplant-free survival to be
88 and 69 %, respectively. TIPS patency in this group of
patients, who have hypercoagulopathy, was best in those
who received a dedicated covered stent [24].
Complications
The procedure-related morbidity and mortality of TIPS are
much lower than for conventional surgical shunts. The
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reported rate of fatal complications is 1.7 % (range
0.6–4.3 %). This rate has been found to be inversely related
to the number of TIPS procedures performed [25]. Fatal
periprocedural complications include intraperitoneal hem-
orrhage as a result of extrahepatic rupture of the portal
vein, laceration of the hepatic artery, and transcapsular
puncture with the transjugular needle.
Postprocedural complications and adverse effects
include impairment of liver function, indicated by an
increase in serum bilirubin concentration; occurrence of
hepatic encephalopathy; and cardiac volume overload,
which might result in deterioration of circulatory function
in patients with cirrhosis and with preexisting heart
insufficiency.
Conclusions
Technical and medical advances have been introduced in
TIPS practice to improve shunt patency and to increase the
effectiveness of hepatic encephalopathy treatment. These
advances will expand the indications for TIPS in the future.
Conflict of interest The authors declare that they have no conflict
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Ro¨sch J, Hanafee WN, Snow H (1969) Transjugular portal
venography and radiologic portacaval shunt: an experimental
study. Radiology 92:1112–1114
2. Boyer TD, Haskal ZJ (2010) AASLD practice guidelines: the role
of transjugular intrahepatic portosystemic shunt (TIPS) in the
management of portal hypertension. Hepatology 51:1–16
3. Stankovic Z, Frydrychowicz A, Csatari Z et al (2010) MR-based
visualization and quantification of three-dimensional flow char-
acteristics in the portal venous system. J Magn Reson Imaging
32:466–475
4. Runyon BA (2009) Management of adult patients with ascites
due to cirrhosis: an update. Hepatology 49:2087–2107
5. Harrod-Kim P, Saad W, Waldman D (2006) Predictors of early
mortality after transjugular intrahepatic portosystemic shunt
creation for the treatment of refractory ascites. J Vasc Interv
Radiol 17:1605–1610
6. Strauss RM, Boyer TD (1997) Hepatic hydrothorax. Semin Liver
Dis 17:227–232
7. Senzolo M, Cholongitas E, Davies N et al (2006) Transjugular
intrahepatic portosystemic shunt (TIPS), the preferred therapeutic
option for Budd Chiari syndrome associated with portal vein
thrombosis. Am J Gastroenterol 101:2163–2164
8. Michl P, Gulberg V, Bilzer M et al (2000) Transjugular intra-
hepatic portosystemic shunt for cirrhosis and ascites: effects in
patients with organic functional renal failure. Scand J Gastroen-
terol 35:654–657
9. Azoulay D, Castaing D, Dennison A et al (1994) Transjugular
intrahepatic shunt worsens the hyperdynamic circulatory state of
the cirrhotic patient: preliminary report of a prospective study.
Hepatology 19:129–132
10. Maleux G, Nevens F, Heye S et al (2006) The use of carbon
dioxide wedged hepatic venography to identify the portal vein:
comparison with direct catheter portography with iodinated
contrast medium and analysis of predictive factors influencing
level of opacification. J Vasc Interv Radiol 17:1771–1779
11. Krajina A, Lojik M (2001) TIPS technique. In: Hulek P, Krajina
A (eds) Current practice of TIPS. Olga Stambergova, Hradec
Kralove, pp 56–120
12. Zizka J, Elias P, Krajina A et al (2000) Value of Doppler
sonography in revealing transjugular intrahepatic portosystemic
shunt malfunction: a 5-year experience in 216 patients. Am J
Roentgenol 175:141–148
13. Carr CE, Tuite CM, Soulen MC et al (2006) Role of ultrasound
surveillance of transjugular intrahepatic portosystemic shunts in
the covered stent era. J Vasc Interv Radiol 17:1297–1305
14. Bass NM, Mullen KD, Sanyal A et al (2010) Rifaximin treatment
in hepatic encephalopathy. N Engl J Med 362:1071–1081
15. Riggio O, Angeloni S, Salvatori FM et al (2008) Incidence, natural
history, and risk factors of hepatic encephalopathy after transjugular
intrahepatic portosystemic shunt with polytetrafluoroethylene-cov-
ered stent grafts. Am J Gastroenterol 103:2738–2746
16. Bureau C, Garcia-Pagan JC, Otal P et al (2004) Improved clinical
outcome using polytetrafluoroethylene-coated stents for TIPS:
results of a randomized study. Gastroenterology 126:469–475
17. Ro¨ssle M, Siegerstetter V, Euringer W et al (2006) The use of a
polytetrafluoroethylene-covered stent graft for transjugular
intrahepatic portosystemic shunt (TIPS): long-term follow-up of
100 patients. Acta Radiologica 7:660–666
18. Riggio O, Ridola L, Lucidi C, Angeloni S (2010) Emerging
issues in the use of transjugular intrahepatic portosystemic shunt
(TIPS) for management of portal hypertension: time to update the
guidelines? Dig Liver Dis 42:462–467
19. Jirkovsky V, Fejfar T, Safka V et al (2011) Influence of the
secondary deployment of expanded polytetrafluoroethylene-cov-
ered stent grafts of maintenance of transjugular intrahepatic
portosystemic shutn patency. J Vasc Interv Radiol 22:55–60
20. Ro¨ssle M, Ochs A, Gulberg V et al (2000) A comparison of
paracentesis and transjugular intrahepatic portosystemic shunting
in patients with ascites. N Engl J Med 342:1701–1707
21. Salerno F, Camma C, Enea M et al (2007) Transjugular intra-
hepatic portosystemic shunt for refractory ascites: a meta-analysis
of individual patient data. Gastroenterology 133:825–834
22. Saugel B, Phillip V, Gaa J et al (2012) Advanced hemodynamic
monitoring before and after transjugular intrahepatic portosys-
temic shunt: implication for selection of patients—a prospective
study. Radiology 262:343–352
23. Garcia-Pagan JC, Caca K, Bureau C et al (2010) Early use of
TIPS in patients with cirrhosis and variceal bleeding. N Engl J
Med 362:2370–2379
24. Garcia-Pagan JC, Heydtmann M, Raffa S et al (2008) TIPS for
Budd-Chiari syndrome: long-term results and prognostics factors
in 124 patients. Gastroenterology 135:808–815
25. Barton RE, Ro¨sch J, Saxon RR et al (1995) TIPS: short- and long-
term results: a survey of 1750 patients. Semin Interv Radiol
12:346–367
1300 A. Krajina et al.: Quality Improvement for TIPS
123
